Antiangiogenic tyrosine kinase inhibitors in metastatic colorectal cancer: focusing on regorafenib
M Papadimitriou, CA Papadimitriou - Anticancer Research, 2021 - ar.iiarjournals.org
The progress of metastatic colorectal cancer (mCRC) depends essentially on two signaling
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
M Papadimitriou, CA Papadimitriou - Anticancer research, 2021 - pubmed.ncbi.nlm.nih.gov
The progress of metastatic colorectal cancer (mCRC) depends essentially on two signaling
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
[PDF][PDF] Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
M PAPADIMITRIOU… - ANTICANCER …, 2021 - ar.iiarjournals.org
The progress of metastatic colorectal cancer (mCRC) depends essentially on two signaling
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
M Papadimitriou, CA Papadimitriou - Anticancer Research, 2021 - europepmc.org
The progress of metastatic colorectal cancer (mCRC) depends essentially on two signaling
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …